Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03315039 |
|
Recruitment Status :
Recruiting
First Posted : October 19, 2017
Last Update Posted : December 10, 2018
|
Sponsor:
Moleculin Biotech, Inc.
Information provided by (Responsible Party):
Moleculin Biotech, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2019 |
| Estimated Study Completion Date : | July 2019 |